UK MHRA Explains Procedures For On-Site Inspections In COVID-19 Context
Executive Summary
New guidance explains how UK-based sites and organizations can facilitate routine on-site good practice inspections that are due to restart next month.
You may also be interested in...
MHRA Prepares For Safe Return To On-Site Inspections In UK
Four months after suspending all non-essential on-site inspections because of the COVID-19 pandemic, the UK medicines regulator is busy finalizing the practical arrangements needed to resume these safely at local sites.
COVID-19: UK MHRA Says Non-Essential Inspections Will Be Office-Based
The UK’s Medicines and Healthcare products Regulatory Agency is replacing all non-essential on-site inspections with office-based assessments due to the coronavirus pandemic. The agency also plans to rely on information from international regulatory partners to maintain oversight.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.